Fulcrum shares plunged to a 52-week low of about $2.90 after the company halted development of its lead sickle cell disease drug, pociredir. ・Heron shares fell to a record low of $0.44 after a federal ...
Fintel reports that on November 12, 2025, D. Boral Capital maintained coverage of MicroVision (NasdaqGM:MVIS) with a Buy recommendation. As of November 8, 2025, the average one-year price target for ...
MicroVision, Inc. (NASDAQ:MVIS) is one of the best augmented reality penny stocks to buy. On May 13, MicroVision, Inc. (NASDAQ:MVIS) reported its Q1 2026 financial results, where revenue came in at $0 ...
MicroVision provided 2026 revenue guidance: "We expect revenue to be in the range of $10 million to $15 million. This is based on our analysis completed to date of both prior MicroVision outlook going ...